1 in which patients experience severe fatigue, cognitive slowing, and a variety of other quite limiting symptoms. Some patients with the latter disorder are diagnosed with "chronic Lyme disease" and led to believe this constitutes a difficult-to-treat nervous system infection with B. burgdorferi. Although this divergence of word usage is problematic, several underlying facts appear clear.
First, as evidenced by the IOM study, there is no doubt that there is a large group of individuals, as many as 2 % of the population, 2 is no plausible pathophysiologic mechanism to explain these symptoms.
Some have suggested that given that even current diagnostic tests are not 100 % sensitive, and given the challenges of treating nervous system infections, perhaps, in the absence of other options, patients with the symptom complex referred to as "chronic Lyme" should be treated aggressively for possible neuroborreliosis anyway. The problem here is that multiple studies have clearly shown that additional and prolonged courses of antimicrobial therapy do not benefit these patients, but do carry significant risk of harm. Treated patients can develop antibioticassociated diarrhea, allergic reactions, and intravenous access-site infections among other complications. Such antibiotic overuse also clearly contributes to the increasing prevalence of antibiotic-resistant microbes [14] [15] [16] [17] affecting the broader population. Perhaps paradoxically, while prolonged treatment is said to be needed for these patients thought to have a small bacterial load, 18 it is quite clear that parenchymal CNS neuroborreliosis is highly responsive to limited courses of parenteraland probably even oral-antibiotics. 18 Despite major improvements in diagnostic testing, some still assume incorrectly that test sensitivity is poor. As with any serologic test, it takes time for sufficient antibodies to be produced to be identifiable. In Lyme disease within 4-6 weeks of initial infection, virtually all patients will have positive two-tiered serologic testing (screening with an enzyme-linked immunosorbent assay [ELISA], confirmed by Western blot, the current standard). 19 Measurement of antibody to a specific antigenic domain, C6, appears to be quite sensitive as well and is being increasingly adopted contrast enhancing) evidence of focal CNS infection. 8 In patients with such focal CNS parenchymal infection, intrathecal antibody production is virtually always present. Finally, neurologic disease that clearly is due to CNS infection is almost invariably cured by 2-to 4-week courses of conventional antibiotics, likely including oral doxycycline. 18 Given these basic facts, how do we best try to help patients with possible nervous-system Lyme disease and patients with SEID or "chronic Lyme disease?" As should be clear, diagnosis and treatment of the former is generally straightforward. For the latter, while acknowledging the disabling nature of this symptom complex in many patients, and the need for a far-better understanding of its pathophysiology and treatment, we should also understand that there is no evidence that it is caused by chronic, insidious infection with B. burgdorferi-either within or outside the nervous system. Nor is there evidence that prolonged and unconventional antimicrobial therapy provides any significant or lasting benefit. In approaching such individuals, we need to balance our wish to help with the necessity of first doing no harm. n
